...mos of diagnosis. Logistic regression estimated effects of race, age, income, Medicaid enrollment, urban residence and y...
...mos (p<0.001). Overall survivals (OS) were (mos): 29.6, 23.8, 31.2, 67.2, 59.5+ for Overall, G1, G2, G3, and G4, respect...
...mos. Median PFS for all responders and CR pts were 23.4 mos and 30.4 mos, respectively. Twenty-three pts (74%) reported ...
...mos (range 0.03-19.5 mos). Prior therapy in addition to imatinib, included interferon (58 pts), dasatinib and/or nilotin...
...mos] versus FC [22 mos]) (P=0.031). In both groups, CR was associated with relief from all predefined CLL symptoms for ≥...
...mos. Progression-free survival (PFS) at 24 mos was 80% (75% in imatinib-resistant and 94% in imatinib-intolerant pts). O...
...mos; average number of PHLs per year ranged from 0-23 (mean=9). After 1 year of imatinib, PHLs ranged from 0 to 9 (mean=...
...mos. Three of 5 patients with data available had a Bcr-Abl mutation at baseline. HR occurred in 14 (64%) pts of which 10...
...mos. BCR-ABL mutations associated with imatinib resistance were detected in 11/17 (65%) pts at baseline. The median dura...
...mos versus 19.2 mos) compared to F. CR and OR were not significantly different based on interphase cytogenetics, IgV sta...
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话: 0531-88819269